Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) - USD ($)			1 Months Ended			3 Months Ended		6 Months Ended
	Feb. 27, 2014	Jul. 24, 2012	Dec. 21, 2015	Apr. 22, 2014	Jun. 15, 2012	Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015	Feb. 16, 2016	Dec. 31, 2015	Sep. 30, 2014
Commitments and Contingencies (Textual)
Research recorded fees						$ 4,147,945	$ 3,837,959	$ 7,913,397	$ 7,886,673
Letter of credit				$ 34,733
Sub lease agreement expiration date				Sep. 30, 2016
Cost of lease agreement								16,620
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost for clinical trial of Iomab-B	$ 5,700,000							1,900,000
Non - refundable institutional fee	$ 600,000
Total project estimated to cost						100,000		100,000			$ 100,000
Research and development costs								200,000	3,500,000
Einstein [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost						200,000		200,000				$ 200,000
Research and development costs								36,678	55,000
AbbVie Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment								3,000,000
Milestones payments								$ 7,750,000
Description of royalty payment								The Company shall pay to AbbVie Biotherapeutics Corp. on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage								12.00%
First commercial sale period								12 years 6 months
AbbVie Biotherapeutics Corp [Member] \| After first net sales [Member]
Commitments and Contingencies (Textual)
Milestones payments								$ 1,500,000
AbbVie Biotherapeutics Corp [Member] \| Phase 1 Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments		$ 750,000						750,000
Abbott Biotherapeutics Corp [Member] \| After first net sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment								10,000,000
Oak Ridge National Laboratory [Member]
Commitments and Contingencies (Textual)
Research and development costs			$ 900,000					$ 300,000	200,000
Icon Clinical Research [Member]
Commitments and Contingencies (Textual)
Down payment of project estimated cost percentage								12.50%
Down payment for project								$ 1,900,000
Down payment paid in 2007 and 2012								200,000
Total project estimated to cost						$ 2,700,000		2,700,000
Research and development costs								$ 300,000	200,000
Fred Hutchinson Cancer Research Center [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones payments					$ 1,000,000
Description of royalty payment								Royalty payments of 2% of net sales will be due to FHCRC.
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )					200,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )					300,000
Research recorded fees								$ 400,000	$ 200,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration					30,000,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration					$ 25,000,000
Medpace, Inc. [Member] \| CRO Agreement [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost										$ 7,200,000
Research and development costs								$ 1,600,000